Glucocorticoids and B-cell targeting therapies are the cornerstones of IgG4 disease treatment, according to data presented at ...
SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...
NANJING, China and GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical stage biopharmaceutical ...
After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median duration of response was 18.1 months, progression ...
A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...
Matching-adjusted indirect comparison of bireociclib plus fulvestrant versus abemaciclib plus fulvestrant as second-line treatment of HR+/HER2− advanced breast cancer. This is an ASCO Meeting Abstract ...
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results